ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2680

DNA Hydroxymethylation Changes in CD4+T Cells from Patients with Systemic Lupus Erythematosus

Ming Zhao, Wei Liao, Bochen Zhu, Ruifang Wu and Qianjin Lu, Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: DNA Methylation, Gene Expression, T cells and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: T and B Cell Signaling and Genetic Variants

Session Type: Abstract Submissions (ACR)

Background/Purpose

Recent studies have uncovered 5-hydroxymethylcytosine (5hmC) as the sixth base of the genome, and that the Ten-eleven translocation (TET) family proteins is responsible for the generation of 5hmC from 5mC in mammalian cells. 5hmC may function as another epigenetic mark by altering chromatin structure or contributing to the recruitment or exclusion of other DNA-binding proteins that affect transcription. However, the report about DNA hydroxymethylation in CD4+ T cell or SLE is poor, though DNA hypomethylation has been confirmed to contribute to SLE. In this study, we will investigate DNA hydroxymethylation in genome-wide in lupus CD4+ T cells.

Methods

36 SLE patients and 36 healthy controls were recruited. CD4+ T cells were isolated by magnetic beads. The age and sex are matched. All patients fulfilled at least 4 of the SLE classification criteria of ACR. The content of 5hmC in genome was detected by dot blot. hMeDIP-NimbleGen Human 3x720K Promoter Plus CpG Island Arrays was completed for identification of genes with different 5hmC modifications between SLE CD4+ T cells and normal controls. mRNA expression levels were measured by real-time RT-PCR. Gene ontology (GO) was analyzed by the Database for Annotation, Visualization and Integrated Discovery (DAVID). Student’s t-test for equality of means was used to compare values. P-values < 0.05 were considered as significant.

Results

Compared with normal controls, the content of 5hmC was increased significantly in lupus CD4+ T cells according to the result of dot blot. hMeDIP-chip and data analysis showed 2753 genes with increased 5hmC and 50 genes with decreased 5hmC within their promoter regions in lupus CD4+ T cells. Through the integrated analysis of DNA hydroxymethylation data with DNA methylation data from our previous study, we found 404 genes with increased 5hmC and decreased 5mC in promoter regions in lupus CD4+ T cells, such as UBE2A, IRF1, JUND. In addition, the integrated analysis of DNA hydroxymethylation data with gene expression data from our previous study showed 211 genes with increased promoter hydroxymethylation and expression in lupus CD4+ T cells, such as TNFRSF4, IL15RA and NR2F6, in which some significant GO enrichments, including T cell proliferation and cytokine-mediated signaling pathway, were observed. Furthermore, the results from real-time PCR showed that mRNA expression levels of TET2, TET3, UBE2A and JUND were up-regulated signficantly in CD4+T cells of SLE patients compared with normal controls. The positive correlation was observed between TET2 or TET3 and UBE2A or JUND expression levels.

Conclusion

The increased 5hmC may contribute to DNA demethylation and overexpression of some genes in lupus CD4+ T cells, which suggest DNA hydroxymethylation play an important role in the aberrant epigenetic mechanisms of SLE.


Disclosure:

M. Zhao,
None;

W. Liao,
None;

B. Zhu,
None;

R. Wu,
None;

Q. Lu,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dna-hydroxymethylation-changes-in-cd4t-cells-from-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology